Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
Retrieved on:
Thursday, February 17, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, CARE, Cough, Urine, Fatigue, Perception, Private Securities Litigation Reform Act, SARS, Infection, RT, Therapy, TCM, Population, Mucus, Assessment, Hospital, COVID-19, Caregiver, Chest pain, Chills, Company, Patient, Research, Lupus, Life, Industry, NASDAQ, Headache, Risk, Arthralgia, Breathe Me, Palpitations, Tightness, Parent, Brain, Death, Dizziness, SLE, Medicine, Asthma, Memory, Quality of life, Cancer, Time, Pfizer–BioNTech COVID-19 vaccine, Enthusiasm, Holism, Pressure, Fever, Annual report, Myalgia, AstraZeneca, Lists of diseases, Liver, Nausea, Negative, Somnolence, Pharmaceutical industry, Health insurance, Medical imaging, EARTH, ASEAN, EARTH Efficacy Trial, EARTH’s Results, RGC-COV19TM, Regencell Bioscience Holdings Limited and Regencell Bioscience Asia Limited: Breakthrough in TCM formulae designed to save and improve lives, EARTH EFFICACY TRIAL, EARTH’S RESULTS, RGC-COV19TM, REGENCELL BIOSCIENCE HOLDINGS LIMITED AND REGENCELL BIOSCIENCE ASIA LIMITED: BREAKTHROUGH IN TCM FORMULAE DESIGNED TO SAVE AND IMPROVE LIVES
Based on the above-mentioned criteria, patients who were asymptomatic were rejected and 37 random individuals eventually qualified for enrolment and were enrolled.
Key Points:
- Based on the above-mentioned criteria, patients who were asymptomatic were rejected and 37 random individuals eventually qualified for enrolment and were enrolled.
- The enrolled patients were between the ages of 5 to 61 and of different races, ethnic backgrounds and socioeconomic backgrounds.
- Out of the 37 COVID-19 patients, 36 patients had all symptoms eliminated, save for Sensory Dysfunction and occasional cough, within the 6-day treatment period.
- In conducting EARTH, the treatment was limited to 6 days in order to evaluate its efficacy in reducing and eliminating COVID-19 symptoms.